High-Throughput Carrier Screening Using TaqMan Allelic Discrimination

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Fedick, Anastasia ^a,b   Su, Jing ^b   Jalas, Chaim ^c   Northrop, Lesley ^b   Devkota, Batsal ^b   Ekstein, Josef ^d   Treff, Nathan R ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b REPRODUCTIVE MEDICINE ASSOCIATES OF NEW JERSEY   (United States)

^c Bonei Olam   (United States)

^d Dor Yeshorim   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPLICON; ARTICLE; BLM GENE; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GBA GENE; GENE; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOTE DETECTION; HEXA GENE; HIGH RISK POPULATION; HIGH THROUGHPUT SCREENING; HUMAN; IKBKAP GENE; INDEL MUTATION; INTERMETHOD COMPARISON; JEW; POINT MUTATION; POLYMERASE CHAIN REACTION; PSEUDOGENE; REPRODUCIBILITY; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

ALLELES; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HETEROZYGOTE DETECTION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JEWS; MALE; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS;

EID: 84875434642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059722     Document Type: Article

References (32)

1. Bray SM, Mulle JG, Dodd AF, Pulver AE, Wooding S, et al. (2010) Signatures of founder effects, admixture, and selection in the Ashkenazi Jewish population. PNAS 107 (37): 16222-16227.
2. Kronn D, Jansen V, Ostrer H, (1998) Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population: the first 1000 cases at New York University Medical Center, New York, NY. Arch Intern Med 158: 777-781.
3. Zuckerman S, Lahad A, Shmueli A, Zimran A, Peleg L, et al. (2007) Carrier Screening for Gaucher Disease: Lessons for Low-Penetrance, Treatable Diseases. JAMA 298 (11): 1281-1290.
4. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, et al. (2004) Cystic Fibrosis Population Carrier Screening: 2004 Revision of American College of Medical Genetics Mutation Panel. Genet Med 6 (5): 387-391.
5. Gross SJ, Pletcher BA, Monaghan KG, (2008) Carrier Screening in Individuals of Ashkenazi Jewish Descent. Genet Med 10 (1): 54-56.
6. Shi MM, (2001) Enabling Large-Scale Pharmacogenetic Studies by High-Throughput Mutation Detection and Genotyping Technologies. Clin Chem 47 (2): 164-172.
7. Tsuchihashi Z, Dracopoli NC, (2002) Progress in high throughput SNP genotyping methods. Pharmacogenomics J 2: 103-110.
8. Scott SL, Edelmann L, Liu L, Luo M, Desnick RJ, et al. (2010) Experience with Carrier Screening and Prenatal Diagnosis for Sixteen Ashkenazi Jewish Genetic Diseases. Hum Mutat 31 (11): 1240-1250.
9. Monaghan KG, Feldman GL, Palomaki GE, Spector EB, (2008) Ashkenazi Jewish Reproductive Screening Working Group, et al (2008) Technical Standards and Guidelines for Reproductive Screening in the Ashkenazi Jewish Population. Genet Med 10 (1): 57-72.
10. Farkas DH, Miltgen NE, Stoerker J, van den Boom D, Highsmith WE, et al. (2010) The Suitability of Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry in a Laboratory Developed Test Using Cystic Fibrosis Carrier Screening as a Model. J Mol Diagn 12 (5): 611-619.
11. Schrijverm I, Külm M, (2007) Gardner PI, Pergament EP, Fiddler MB, (2007) Comprehensive Arrayed Primer Extension Array for the Detection of 59 Sequence Variants in 15 Conditions Prevalent Among the (Ashkenazi) Jewish Population. J Mol Diagn 9 (2): 228-236.
12. Shen GQ, Abdullah KG, Wang QK, (2009) The TaqMan Method for SNP Genotyping. Methods Mol Biol 578: 293-306.
13. Schleinitz D, DiStefano JK, Kovacs P, (2011) Targeted SNP Genotyping Using the TaqMan® Assay. Methods Mol Biol 700: 77-87.
14. Hui L, DelMonte T, Ranade K (2008) Genotyping Using the TaqMan Assay. Curr Protoc Hum Genet Chapter 2: Unit 2.10.
15. Robledo R, Beggs W, Bender P, (2003) A simple and cost effective method for rapid genotyping of insertion/deletion polymorphisms. Genomics 82: 580-582.
16. Fedick A, Su J, Treff NR, (2012) Development of TaqMan allelic discrimination based genotyping of large DNA deletions. Genomics 99: 127-131.
17. Tan EL, Yong LLG, Quak SH, Yeo WCA, Chow VTK, et al. (2008) Rapid detection of Enterovirus 71 by real-time TaqMan RT-PCR. J Clin Virol 42: 203-206.
18. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2011) Primer sequence disclosure: a clarification of the MIQE guidelines. ClinChem 57 (6): 919-921.
19. Chambers JM, Cleveland WS, Kleiner B, Tukey PA (1983) Graphical Methods for Data Analysis. California:Wadsworth International Group. 62 p.
20. Rohlfs EM, Zhou Z, Heim RA, Nagan N, Rosenblum LS, et al. (2011) Cystic Fibrosis Carrier Testing in an Ethnically Diverse US Population. ClinChem 57 (6): 841-848.
21. Fares F, Badarneh K, Abosaleh M, Harari-Shaham A, Diukman R, et al. (2008) Carrier frequency of autosomal-recessive disorders in the Ashkenazi Jewish population: should the rationale for mutation choice for screening be reevaluated? Prenat Diagn 28 (3): 236-241.
22. Reish O, Borochowitz ZU, Adir V, Shohat M, Karpati M, et al. (2009) Dynamic modification strategy of the Israeli carrier screening protocol: inclusion of the Oriental Jewish Group to the cystic fibrosis panel. Genet Med 11 (2): 101-103.
23. Wang J, Lin M, Crenshaw A, Hutchinson A, Hicks B, et al. (2009) High-throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic Arrays. BMC Genomics 10: 561.
24. Gómez-Fernández N, Castellví-Bel S, Fernández-Rozadilla C, Balaguer F, Muñoz J, et al. (2009) Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: a different spectrum of mutations. BMC Med. Genet 10: 57.
25. Fedick A, Su J, Jalas C, Treff NR, (2012) High-throughput real-time PCR-based genotyping without DNA purification. BMC Res Notes 5: 573.
26. Tzvetkov MV, Meineke I, Sehrt D, Vormfelde SV, Brockmöller J, (2010) Amelogenin-based sex dentification as a strategy to control the identity of DNA samples in genetic association studies. Pharmacogenomics 11 (3): 449-457.
27. Winfield SL, Tayebi N, Martin BM, Ginns El, Sidransky E, (1997) Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res 7 (10): 1020-1026.
28. Brown JT, Lahey C, Laosinchai-Wolf W, Hadd AG, (2006) Polymorphisms in the glucocerebrosidase gene and pseudogene urge caution in clinical analysis of Gaucher disease allele c.1448T>C (L444P). BMC Med. Genet 7: 69.
29. Horowitz M, Tzuri G, Eyal N, Berebi A, Kolodny EH, et al. (1993) Prevalence of Nine Mutations among Jewish and Non-Jewish Gaucher Disease Patients. Am J Hum Genet 53 (4): 921-930.
30. Jeong SY, Kim SJ, Yang JA, Hong JH, Lee SJ, et al. (2011) Identification of a novel recombinant mutation in Korean patients with Gaucher disease using a long-range PCR approach. J Hum Genet 56 (6): 469-471.
31. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, et al. (2000) Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher Disease. Am J Hum Genet 66 (6): 1777-1786.
32. Treff NR, Fedick A, Tao X, Devkota B, Taylor D, et al. (2013) Evaluation of targeted next-generation sequencing-based preimplantation genetic diagnosis of monogenic disease. Fertil Steril doi: 10.1016/j.fertnstert.2012.12.018.